-- 月曜日の取引開始前、米国株先物は下落した。米国がイランの港湾封鎖を突破しようとしたイランの貨物船を拿捕し、イランがパキスタンで米国との和平交渉再開を拒否したことを受け、中東情勢が再び緊迫したためだ。 ダウ工業株30種平均先物は0.6%安、S&P500先物は0.6%安、ナスダック先物は0.5%安となった。 米国は火曜日にイランとの2週間の停戦が終了する前に交渉を再開したいと表明していたが、イラン外務省は、封鎖が継続していることと米国の「過剰な要求」を理由に、新たな協議には参加しないとした。 週末、イランはホルムズ海峡を通過する船舶に対する独自の封鎖を一時的に解除した後、再び実施している。 今週四半期決算を発表すると予想される企業には、火曜日の取引開始前にGEエアロスペース(GE)とユナイテッドヘルス・グループ(UNH)、水曜日の取引終了後にテスラ(TSLA)とIBM(IBM)、木曜日の取引終了後にインテル(INTC)、金曜日の取引開始前にプロクター・アンド・ギャンブル(PG)などがある。 原油価格は上昇し、北海ブレント原油の期近先物は4.8%高の1バレル94.73ドル、米国産WTI原油は5.7%高の1バレル87.29ドルとなった。 経済指標発表予定日は空いている。
Related Articles
Biocytogen Pharmaceuticals Turns to Profit in Q1
Biocytogen Pharmaceuticals (Beijing) (HKG:2315) recorded an attributable profit of 104 million yuan in the first quarter of 2026, compared with an attributable loss of 13.2 million yuan a year prior, according to a Monday Hong Kong bourse filing.Earnings per share stood at 0.23 yuan, compared with a loss per share of 0.03 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 74% in the three months to 433.1 million yuan from 249.3 million yuan in the year-ago period, driven by a substantially higher revenue contribution from pharmacology and efficacy services and animal models.The pharmaceutical company attributed the higher profit mainly to revenue growth and improved operating efficiency amid expense management.
Market Chatter: LNG Carrier Orders Surge as Global Output Defies Iran War Tensions
Global demand for liquefied natural gas carriers is rebounding sharply in 2026, despite the ongoing US-Iran conflict, Reuters reported Monday, citing analysts and industry experts.Analysts report that surging LNG production and a transition toward high-efficiency vessels are fueling the recovery.According to the report, Shipbuilders in South Korea and China have already secured 35 new build contracts in Q1 alone.The resurgence in construction comes despite the escalating US-Iran war, which has choked the Strait of Hormuz and raised fears of a prolonged shipping downturn.However, market experts suggest that the need for modern, fuel-efficient tonnage is outweighing immediate freight rate concerns, it said.These new vessels, which cost between $250 million and $260 million and take over three years to complete, are increasingly necessary as older, steam-propelled tankers are scrapped at record rates to meet stricter global emissions regulations.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Canaccord Genuity Initiates Coverage on Structure Therapeutics With Buy Rating, $101 Price Target
Structure Therapeutics (GPCR) has an average rating of Buy and mean price target of $108.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)